Evidence map›Paper›PMID 34158941›Full record

ArticleSAGE open medicine2021

U.S. student pharmacist perceptions of the pharmacist's role in methadone for opioid use disorder: A qualitative study.

Kenneth C Hohmeier, Alina Cernasev, Megan Sensmeier, Elizabeth Hall, Katie Webb, Rachel Barenie, Gerald Cochran

Open access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Demographic and socioeconomic correlates to buprenorphine access in pharmacies.Journal of the American Pharmacists Association : JAPhA
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kenneth C HohmeierDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Nashville, TN, USA.ORCID https://orcid.org/0000-0002-0060-4643
Alina CernasevDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Nashville, TN, USA.
Megan SensmeierDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Nashville, TN, USA.
Elizabeth HallDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Nashville, TN, USA.
Katie WebbPathway Healthcare, Nashville, TN, USA.ORCID https://orcid.org/0000-0002-2759-8677
Rachel BarenieDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, The University of Tennessee Health Science Center, Nashville, TN, USA.
Gerald CochranSchool of Medicine, University of Utah, Salt Lake City, UT, USA.
University of Tennessee Health Science Center · USPathways Behavioral Services · USUniversity of Utah · US

Funding

Greater Intermountain Node (CTN-0151)UG1DA049444 · NIDA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Gerald T. Cochran, Gerald T. Cochran · 2019 to 2026
$16.8M
NIDA NIH HHS UG1 DA049444
6 · The paper itself

Abstract

backgroundOf the over 20 million Americans reporting an opioid use disorder, only around 3 million report receiving treatment of any kind. The gold standard for opioid use disorder treatment is medication in combination with psychosocial support, but despite robust evidence supporting treatment, barriers are substantial and include limited insurance coverage, patient beliefs, ease of access, regulatory hurdles, and stigma. Although trained as medication experts, U.S. pharmacists are not routinely involved in opioid use disorder treatment and may represent an underutilized care team member.

objectiveTo explore U.S. pharmacy students' perspectives on pharmacists as providers of methadone-based medications for opioid use disorder treatment.

methodsA qualitative design with focus groups of student pharmacists in a U.S. college of pharmacy in the Southeastern United States.

resultsOver 2 months in 2020, three focus groups were conducted with 15 students in each group participating, and including second-, third-, and fourth-year student pharmacists. Three overarching themes emerged from the data: (1) student pharmacists desire exposure to therapeutic knowledge and lived experiences related to opioid use disorder and methadone treatment, (2) students perceive stigmatizing views held by practicing pharmacists toward opioid use disorder and methadone treatment, (3) pharmacists should play a role in methadone treatment.

conclusionStudent pharmacists desire an active and larger role in the care of patients managing opioid use disorder. Findings indicate these students perceive less stigma toward opioid use disorder than currently practicing pharmacists. Pharmacy curricula should emphasize stories of lived experiences of patients with opioid use disorder, therapeutic knowledge and guidelines related to medications for opioid use disorder, and the regulatory environment surrounding opioid use disorder treatment.

Indexed as

community practicemethadoneMOUDOpioidsopioid use disorderOUDpain managementpharmacist/physician issues

Identifiers

PMID34158941
PMCPMC8182209
OpenAlexW3173008668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.